• 1
    Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. HEPATOLOGY 2005; 41: 13911398.
  • 2
    Fung SK, Lok AS. Management of hepatitis B patients with antiviral resistance. Antivir Ther 2004; 9: 10131026.
  • 3
    Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. HEPATOLOGY 2001; 34: 785791.
  • 4
    Locarnini S, Qi X, Arterburn S, Snow A, Brosgart C, Currie G, et al. Incidence and predictors of emergence of adefovir resistant HBV during 4 years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) [Abstract]. J Hepatol 2005; 42(Suppl 2): 17.
  • 5
    Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528536.
  • 6
    Westland CE, Yang H, Delaney WEt, Gibbs CS, Miller MD, Wulfsohn M, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. HEPATOLOGY 2003; 38: 96103.
  • 7
    Durantel S, Werle B, Durantel D, Pichoud C, Currie G, Xiong S, et al. Different profiles of response to adefovir dipivoxil and factors that may influence response in patients with chronic hepatitis B [Abstract]. J Hepatol 2004; 40(Suppl 1): 654A.
  • 8
    Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283290.
  • 9
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808816.
  • 10
    Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292297.
  • 11
    Qi X, Snow A, Thibault V, Zhu Y, Curtis M, Hadziyannis S, et al. Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy [Abstract]. J Hepatol 2004; 40(Suppl 1): 20.
  • 12
    Hadziyannis S, Tassopoulos N, Chang T, Heathcote EJ, Kitis G, Rizzetto M, et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy [Abstract]. HEPATOLOGY 2005; 42(Suppl): 754A.
  • 13
    Yeon J, Yoo W, Hong S, Chang Y, Yu S, Kim J, et al. Resistance to adefovir dipivoxil (ADV) in lamivudine-resistant chronic hepatitis B patients treated with ADV Gut 2006;epub Feb. 4, 2006. Accessed May 31, 2006 at
  • 14
    Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. HEPATOLOGY 2006; 43: 13851391.
  • 15
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 10011010.
  • 16
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 10111020.
  • 17
    Colonno R, Rose R, Levine S, Baldick J, Pokornowski K, Plym M, et al. Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refreactory patients [Abstract]. HEPATOLOGY 2005; 42(Suppl): 573A.
  • 18
    Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48: 34983507.
  • 19
    Sherman M, Martin P, Lee W, Yurdaydin C, Sollano J, Vaughan J. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026) [Abstract]. Gastroenterology 2006; 130(Suppl 2): A765.
  • 20
    Yim HJ, Hussain M, Wong SN, Liu Y, Fung S, Lok AS. Evolution of multi-drug resistant HBV: implications on rescue therapy [Abstract]. Gastroenterology 2006; 130 (Suppl 2): A748.
  • 21
    Lacombe K, Gozlan J, Boelle PY, Serfaty L, Zoulim F, Valleron AJ, et al. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS 2005; 19: 907915.
  • 22
    Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16: 23522354.
  • 23
    Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 11851192.
  • 24
    Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, et al. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother 2005; 56: 10871093.
  • 25
    Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. HEPATOLOGY 2006; 43: 548555.
  • 26
    van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppeppe D, Möller B, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. HEPATOLOGY 2006; 44: 318325.
  • 27
    Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354: 18071812.
  • 28
    Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2: 266272.
  • 29
    van Bömmel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. HEPATOLOGY 2004; 40: 14211425.
  • 30
    Peters MG, Anderson J, Lynch P, Jacobson J, Sherman KE, Alton Smith B, et al. Tenofovir disoproxil fumarate is not inferior to adefovir dipivoxil for the treatment of hepatitis B virus in subjects who are co-infected with HIV: results of ACTG A5127 [abstract]. Twelfth Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 22-25, 2005:A124.
  • 31
    Schildgen O, Hartmann H, Gerlich WH. Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication. Scand J Gastroenterol 2006; 41: 245246.
  • 32
    van Bommel F, Berg T. Reactivation of viral replication after replacement of tenofovir by adefovir. HEPATOLOGY 2005; 42: 239240.
  • 33
    Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727734.
  • 34
    Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42: 283290.
  • 35
    Badiou S, De Boever CM, Terrier N, Baillat V, Cristol JP, Reynes J. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? J Infect 2006; 52: 335338.
  • 36
    Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35: 269273.
  • 37
    FDA. Viread (tenofovir disoproxil fumarate) tablets safety report. August 5, 2005. Accessed June 20, 2006, at
  • 38
    Kiser J, Carten M, Wolfe P, King T, Delahunty T, Bushman L, et al. Effect of lopinavir/ritonavir (LPV/r) on the renal clearance (CLr) of tenofovir (TFV) in HIV-infected patients. Thirteenth Conference on Retroviruses and Opportunistic Infections. Denver, CO. February 2006:L-156.
  • 39
    Roling J, Schmid H, Fischereder M, Draenert R, Goebel FD. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006; 42: 14881495.
  • 40
    Squires K, Pozniak AL, Pierone G, Jr., Steinhart CR, Berger D, Bellos NC, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003; 139: 313320.
  • 41
    Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191201.
  • 42
    Antoniou T, Raboud J, Chirhin S, Yoong D, Govan V, Gough K, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med 2005; 6: 284290.